Douglass Winthrop Advisors, LLC Biogen Inc. Transaction History

Douglass Winthrop Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 09, 2019	SELL	$216.71 - $338.96 $301,660 - $471,832	-1,392 Closed	0 $0
Q2 2018 Jul 24, 2018	BUY	$257.52 - $306.91 $19,314 - $23,018	75 Added 5.69%	1,392 $404,000
Q1 2018 May 08, 2018	SELL	$260.13 - $367.91 $320,740 - $453,633	-1,233 Reduced 48.35%	1,317 $361,000
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $784,482 - $878,679	-2,550 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $716,932 - $840,709	2,550	2,550 $0

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Douglass Winthrop Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Douglass Winthrop Advisors, LLC with notifications on news.